Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + pegylated interferon alfa-2b in stage IV metastatic melanoma
2007-001918-16Phase 2Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Apr 2009
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and peginterferon alfa-2b in melanoma, sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Disease control rate at 8 weeks. Started Apr 2009; status: completed.
02
Drugs
sorafenibpeginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-001918-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001918-16.